Who is sponsoring NCT03540953?

NCT03540953 is sponsored by Fauze Maluf Filho.

What drugs are being tested in NCT03540953?

Interventions in NCT03540953: Endoscopic injection of Mitomycin C.

What condition does NCT03540953 study?

NCT03540953 studies Esophageal Stenosis, Deglutition Disorders, Head and Neck Neoplasms, Esophageal Neoplasms.

Is NCT03540953 still recruiting?

NCT03540953 is currently terminated. Last updated 30 May 2018.

Last reviewed 2018-05-30 · How we verify

NCT03540953

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis

Terminated NA Last updated 30 May 2018

What this trial tests

NA trial testing Endoscopic injection of Mitomycin C in Esophageal Stenosis in 12 participants. Terminated before completion.

Timeline

5 January 2015

Primary endpoint
5 May 2015

5 January 2018

Quick facts

Lead sponsor	Fauze Maluf Filho
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	5 January 2015
Primary completion	5 May 2015
Estimated completion	5 January 2018
Sites	1 location across Brazil

Drugs / interventions tested

Endoscopic injection of Mitomycin C — full drug profile →

Conditions studied

Esophageal Stenosis — all drugs for Esophageal Stenosis →
Deglutition Disorders — all drugs for Deglutition Disorders →
Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →
Esophageal Neoplasms — all drugs for Esophageal Neoplasms →

Sponsor

Fauze Maluf Filho — full company profile →

Who can join

18 and older, any sex, with Esophageal Stenosis or Deglutition Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Management of pharyngoesophageal stenosis (PES) in patients after head and neck cancer (HNC) treatment remains a challenge. There are some cases of strictures refractory to dilation sessions. This study aimed to evaluate the efficacy of Mitomycin C (MMC) endoscopic injection for the treatment of refractory pharyngoesophageal stenosis. Patients and methods: This is a prospective study in patients with dysphagia following head and neck cancer treatment, without evidence suggestive of tumor recurrence, and refractory to endoscopic treatment. Theses undergo endoscopic dilation of the stenotic segment with thermoplastic bougies, followed by the injection of MMC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Fauze Maluf Filho trials

Trials by the same sponsor.

NCT02284802 — Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03540953 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fauze Maluf Filho
Last refreshed: 30 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03540953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing